Jory Bell

1910 Genetics Operates as a biotechnology company. The company was founded by Jennifer Nwankwo and is headquartered in Cambridge, MA.

Manifold Biotechnologies, Inc. provides biotechnology services. The company was founded by Gleb Kuznetsov, Pierce Ogden, Shane Lofgren and George Church and is headquartered in Allston, MA.

Ultima Genomics, Inc. is a company that aims to drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. Ultima Genomics is based in Newark, CA. The company has built a revolutionary new sequencing architecture designed to scale far beyond conventional technologies and overcome the cost-driven tradeoffs scientists and clinicians are forced to make between the breadth, depth, and frequency with which they use genomic information. The company was founded by Gilad Almogy, who has been the CEO since incorporation.

Mangata Networks, Inc. is a technology company that provides satellite and terrestrial network solutions for various industries such as terrestrial backhaul, aeromobility, maritime, oil and gas, and IoT. The company was founded in 2020 by Juliette Neu and is based in Gold Canyon, AZ. The company's proprietary technology includes a network of satellite and terrestrial solutions that offer high-capacity and reliable service across the globe. The CEO is Brian Holz.

Amber Bio, Inc. is a biotechnology company based in an undisclosed location. The American company is focused on developing a first-of-its-kind RNA editing platform that can correct genetic mutations in a safe and reversible way. Amber Bio is pioneering new gene editing modalities using multi-kilobase RNA writing to reach previously undruggable diseases. Co-founders Jacob Borrajo and Basem Al-Shayeb received their Ph.D. at leading institutions for gene editing research: Broad Institute of MIT & Harvard and University of California. Jacob Borrajo has been the CEO since incorporation.

Atomic AI Inc. is a biotechnology company that specializes in using artificial intelligence and structural biology to discover and design RNA-based medicines. The company is based in San Francisco, CA, and is backed by an interdisciplinary team of machine learning researchers, medicinal chemists, engineers, and experimental biologists, as well as strategic scientific advisers and world-class investors. The company's proprietary R&D platform integrates deep learning foundation models with purpose-designed, in-house wet-lab assays to treat undruggable diseases. The CEO of the company is Raphael Townshend.